Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, Chen W, Yan Z, Sang W, Qi K, Li D, Zhu F, Li Z, Qiao J, Wu Q, Zeng L, Fei X, Gu W, Miao Y, Xu K, Zheng J, Cao J.
Shi M, et al. Among authors: miao y.
Nat Commun. 2024 Apr 20;15(1):3371. doi: 10.1038/s41467-024-47801-8.
Nat Commun. 2024.
PMID: 38643278
Free PMC article.
Clinical Trial.